butabarbital decreases consequences of sufentanil SL by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Observe Closely. Coadministration of CYP3A4 inducers might decrease sufentanil stages and efficacy, potentially precipitating withdrawal syndrome in patients who may have formulated Actual physical dependence to sufentanil.